Prodrugs of the selective progesterone receptor modulator (SPRM) (11.beta.,17.beta.)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl] -17-(pentafluoroethyl)estra-4,9-dien-3-one

This invention concerns Selective Progesterone Receptor Modulators (SPRM) in a prodrug form as well as to their application in therapy. (3±,11²,17²)-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-diene-3,17-diol (Compound 1) is one of the invention prodrugs.

Saved in:
Bibliographic Details
Main Authors Wagenfeld, Andrea, Militzer, Hans-Christian, Rottmann, Antje, Irlbacher, Horst
Format Patent
LanguageEnglish
Published 19.01.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
STEROIDS
Online AccessGet full text

Cover

More Information
Summary:This invention concerns Selective Progesterone Receptor Modulators (SPRM) in a prodrug form as well as to their application in therapy. (3±,11²,17²)-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-diene-3,17-diol (Compound 1) is one of the invention prodrugs.
Bibliography:Application Number: US201716082025